NCT02596178

Brief Summary

Lung units that participate in gas exchange are known as 'recruited' lung. Patients with lung injury suffer from a proportion of units that do not participate in gas exchange (i.e. the derecruited lung), which results in impaired gas exchange and induces an inflammatory cascade. The level of PEEP is often coupled to indices of oxygenation such as PaO2, PaO2 to FIO2 ratio, or oxygen index. Currently, two strategies are widely accepted and considered equivocal, one strategy using a lower PEEP level coupled to a certain oxygen requirement, the other using a higher PEEP level. The primary purpose of this study is to demonstrate the safety and efficacy of an electrical impedance tomography (EIT) PEEP titration protocol designed to recruit collapsed lung in children with ARDS and properly maintain lung volumes by setting an optimal PEEP level. A safety system has been developed using the ARDSnet FIO2/PEEP High (upper threshold limit) and Low (lower threshold limit) algorithm. Efficacy will be defined as an improvement in lung volume as assessed by electrical impedance tomography, lung compliance and by an improvement in markers of gas exchange. Safety will be defined as the incidence of barotrauma and hemodynamic consequences that occur during the protocol. Those results will be compared to incidences of barotrauma and hemodynamic compromise within the ARDS literature. Knowledge gained from this pilot will be instrumental in developing an EIT imagine guided protocol which will allow us to conduct future RCTs utilizing EIT technology

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 4, 2015

Completed
4 months until next milestone

Study Start

First participant enrolled

March 1, 2016

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
Last Updated

June 5, 2019

Status Verified

June 1, 2019

Enrollment Period

3.8 years

First QC Date

November 2, 2015

Last Update Submit

June 3, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Safety - measured by Barotrauma

    3 days

  • Safety - measured by Gas Exchange

    3 days

Study Arms (1)

EIT Guided PEEP Therapy

EXPERIMENTAL
Device: Electrical Impedance Tomography

Interventions

Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.

EIT Guided PEEP Therapy

Eligibility Criteria

Age2 Years - 35 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • a. The Berlin definition of ARDS36 i. Blood gas criteria:
  • Mild: PaO2/FiO2 ratio of 201-300,
  • Moderate: PaO2/FIO2 ratio of 101-200
  • Severe: PaO2/FIO2 ratio of \< 100 ii. Acute onset (within 1 week) of bilateral (patchy, diffuse, or homogeneous) infiltrates consistent with pulmonary edema on chest radiograph, and iii. No evidence of left atrial hypertension
  • \. Conventional lung protective mechanical ventilation Chest radiograph within the first 12h after the study recruitment

You may not qualify if:

  • Meets the above criteria for ARDS for \> 72 hours
  • \< 2 years of age or chest circumference \< 55 cm.
  • Clinically recognized airways disease (e.g. anatomic or reactive airway disease by history, treatment or flow graphics)
  • Uncuffed endotracheal tube in place
  • Airleak
  • Congenital heart disease
  • Hemodynamically significant heart disease
  • Congenital diaphragmatic hernia
  • Pulmonary fibrosis
  • Restrictive lung disease (other than ARDS)
  • Cystic fibrosis
  • Significant pulmonary hypertension requiring treatment (eg iNO, sildenafil, flolan)
  • Severe brain injury with no intracranial pressure monitor or external ventricular drain in place
  • Extra-corporeal life support
  • Patients with unstable spinal injuries or diseases
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Boston Children's Hospital

Boston, Massachusetts, 02115, United States

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Co-Investigator

Study Record Dates

First Submitted

November 2, 2015

First Posted

November 4, 2015

Study Start

March 1, 2016

Primary Completion

December 1, 2019

Study Completion

July 1, 2020

Last Updated

June 5, 2019

Record last verified: 2019-06

Locations